Nasus Pharma Ltd (NSRX) stock
NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
$2.70+0.09 (+3.45%)
Close on Nov 18, 2026Market cap $24.34MP/E –Yield –
Nasus Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$4.90M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.90M | – |
| FY2024 | Dec 31, 2024 | -$1.08M | – |
| FY2023 | Dec 31, 2023 | -$1.15M | – |
See a number that looks wrong?